Compare CCCC & IMMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCCC | IMMR |
|---|---|---|
| Founded | 2015 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer peripheral equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.1M | 216.7M |
| IPO Year | 2020 | 1999 |
| Metric | CCCC | IMMR |
|---|---|---|
| Price | $2.72 | $6.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $12.20 | ★ $13.50 |
| AVG Volume (30 Days) | ★ 2.9M | 300.0K |
| Earning Date | 05-06-2026 | 02-27-2026 |
| Dividend Yield | N/A | ★ 4.95% |
| EPS Growth | 16.45 | ★ 82.69 |
| EPS | N/A | ★ 1.90 |
| Revenue | ★ $35,947,000.00 | $35,013,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.18 |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $1.09 | $5.65 |
| 52 Week High | $3.82 | $8.15 |
| Indicator | CCCC | IMMR |
|---|---|---|
| Relative Strength Index (RSI) | 51.79 | 49.14 |
| Support Level | $2.35 | $5.77 |
| Resistance Level | $2.71 | $6.39 |
| Average True Range (ATR) | 0.24 | 0.19 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 15.79 | 50.81 |
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.